Temsirolimus

Drug Profile

Temsirolimus

Alternative Names: CCI-779; Cell cycle inhibitor-779; NSC-683864; Torisel

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Johann Wolfgang Goethe Universitatsklinikum; Multiple Myeloma Research Consortium; NCIC Clinical Trials Group; Pfizer; Wyeth
  • Class Antineoplastics; Macrolides
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Mantle-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Renal cell carcinoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Glioblastoma; Glioma; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Phase I/II Follicular lymphoma; Head and neck cancer
  • Phase I Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • No development reported Colorectal cancer; Multiple myeloma; Prostate cancer
  • Discontinued Breast cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Metastatic disease) in Germany (IV, Infusion)
  • 19 Sep 2017 Johannes Gutenberg University Mainz and Pfizer completes a phase I/II trial in Follicular lymphoma or Mantle cell lymphoma in Germany (NCT01078142)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top